| |OCTOBER 20249GLOBAL CRDMO WORK DISTRIBUTION IN INDIA EXPECTED TO RISE UP TO 10 PERCENT BY 2033HOTH THERAPEUTICS SECURES US PATENT FOR ALZHEIMER'S TREATMENTThe global CRDMO (Contract Research Development & Manufacturing Organisation) industry is about to witness a re-distribution of outsourcing work across several Asian countries, with India and Korea emerging as new powerhouses by 2033. At the recent Scale-Up Health event by Eight Roads Ventures, McKinsey & Company presented survey findings that showed that global pharmaceutical companies are increasingly considering India as a destination for their outsourcing needs. Conceptualized and championed by Eight Roads Ventures, Scale-Up Health is India's first platform for healthcare and life sciences entrepreneurs and leaders, which brings together the Indian entrepreneurial ecosystem to drive collaboration, build stronger networks and champion innovation. It aims to spotlight conversations on latest trends, innovations, and technologies that are redefining global healthcare delivery, accessibility and outcomes. This year, the conference explored four disruptive trends for 2025 and beyond. Sharing insights from the survey, Anirudh Roy Popli, Partner, McKinsey & Company, said, The biopharma industry is increasingly recognizing the value Indian CDMOs bring to the table. We are seeing increased interest levels across customer segments. However, building trust and long-term, at-scale partnerships takes time. With a strong focus on value and innovation, Indian CDMOs are well-positioned to play a pivotal role in shaping the future of healthcare". POHoth Therapeutics, Inc., a company in the clinical stage of biopharmaceuticals that specializes in creating new treatments, is excited to share the news of receiving a US patent for their cutting-edge Alzheimer's treatment, HT-ALZ. This significant patent protects the company's unique treatment method, as Hoth speeds up preparations for clinical trials.HT-ALZ is a significant advancement in the treatment of Alzheimer's disease, focusing specifically on the Substance P/Neurokinin-1 Receptor pathway. This pathway is understood to have an important function in neuroinflammation, which is being more widely acknowledged as a key factor in the advancement of Alzheimer's disease. Preclinical research has demonstrated encouraging outcomes, such as decreased neuroinflammation and notable enhancements in cognitive abilities like memory and learning.The patent strengthens Hoth's position in the advancement of Alzheimer's treatments and prepares for the upcoming stage of human trials. Development of HT-ALZ for these tests is currently in progress, aiming to move this encouraging therapy to patients quickly.Once the formulation phase is finished, Hoth Therapeutics will begin to plan clinical trials to confirm the effectiveness of HT-ALZ in humans. The future trials will concentrate on showing the drug's ability to be safe, well-tolerated, and effective in reducing or reversing the cognitive deterioration linked to Alzheimer's disease. PO
< Page 8 | Page 10 >